BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+6.86%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.54B
AUM Growth
+$74.3M
(+1.7%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$39.2M |
| 2 |
Immunocore
IMCR
|
$38.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$36.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
$20M |
| 5 |
Edgewise Therapeutics
EWTX
|
$17.7M |
Top Sells
| 1 |
Incyte
INCY
|
$35.5M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$29.9M |
| 3 |
Intuitive Surgical
ISRG
|
$25.6M |
| 4 |
Boston Scientific
BSX
|
$20M |
| 5 |
Cencora
COR
|
$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Technology | 0.01% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Oculis Holding
OCS
$898M
| $188K | ﹤0.01% |
9,700
-4,400
| -31% | -$85.4K |
|
127
PTC Therapeutics
PTCT
$4.61B
| $186K | ﹤0.01% |
3,800
| – | – |
|
128
Garmin
GRMN
$45.7B
| $177K | ﹤0.01% |
850
| – | – |
|
129
Krystal Biotech
KRYS
$4.33B
| $172K | ﹤0.01% |
1,250
-1,400
| -53% | -$192K |
|
130
Baidu
BIDU
$33.8B
| $172K | ﹤0.01% |
2,000
| – | – |
|
131
Oracle
ORCL
$626B
| $143K | ﹤0.01% |
654
| – | – |
|
132
MoonLake Immunotherapeutics
MLTX
$3.79B
| $142K | ﹤0.01% |
3,000
| – | – |
|
133
Cytokinetics
CYTK
$5.95B
| $124K | ﹤0.01% |
3,741
| – | – |
|
134
NVIDIA
NVDA
$4.18T
| $119K | ﹤0.01% |
751
| – | – |
|
135
Zoetis
ZTS
$67.9B
| $102K | ﹤0.01% |
657
-2,457
| -79% | -$383K |
|
136
Microsoft
MSFT
$3.78T
| $101K | ﹤0.01% |
203
| – | – |
|
137
Agilent Technologies
A
$36.4B
| $95.1K | ﹤0.01% |
806
| – | – |
|
138
Qualcomm
QCOM
$172B
| $71.2K | ﹤0.01% |
447
| – | – |
|
139
Biogen
BIIB
$20.5B
| $50.5K | ﹤0.01% |
402
| – | – |
|
140
Mettler-Toledo International
MTD
$26.5B
| $49.3K | ﹤0.01% |
42
| – | – |
|
141
Recursion Pharmaceuticals
RXRX
$1.97B
| $27.9K | ﹤0.01% |
5,514
-189,538
| -97% | -$959K |
|
|
TEM
142
Tempus AI, Inc. Class A Common Stock
TEM
$13.6B
| $15.1K | ﹤0.01% |
237
| – | – |
|
143
Altimmune
ALT
$314M
| – | – |
-1,056,793
| Closed | -$5.28M |
|
144
Bio-Rad Laboratories Class A
BIO
$7.83B
| – | – |
-21,476
| Closed | -$5.23M |
|
145
Bruker
BRKR
$4.52B
| – | – |
-335,288
| Closed | -$14M |
|
146
Castle Biosciences
CSTL
$670M
| – | – |
-301,103
| Closed | -$6.03M |
|
147
Esperion Therapeutics
ESPR
$510M
| – | – |
-9,694,064
| Closed | -$14M |
|
148
Evolent Health
EVH
$1.1B
| – | – |
-614,337
| Closed | -$5.82M |
|
149
Vaxcyte
PCVX
$4.17B
| – | – |
-11,290
| Closed | -$426K |
|
150
Dr. Reddy's Laboratories
RDY
$11.8B
| – | – |
-91,916
| Closed | -$1.21M |
|